Accretion Nutraveda Reports Doubled FY26 Profit and Revenue

Accretion Nutraveda Ltd reported strong FY26 results, with revenue from operations soaring to ₹33.60 crore. The company's profit for the year ended March 31, 2026, reached ₹5.07 crore, more than double the previous fiscal.

FY26 Financial Results

Accretion Nutraveda Limited announced its audited financial results for the fiscal year ending March 31, 2026. The company posted a profit of ₹506.83 lakh (₹5.07 crore), a substantial increase from ₹250.09 lakh (₹2.50 crore) in FY25.

Revenue from operations grew to ₹3360.31 lakh (₹33.60 crore) for FY26, up from ₹1600.18 lakh (₹16.00 crore) in the prior year. This marks a more than doubling of both key financial metrics.

The board also confirmed the reappointment of M/s. Sakhiya & Co. as Secretarial Auditors and appointed M/s. UMT & Co. as Internal Auditors for FY27. The statutory auditors, M/s. VSSB & Associates, issued an unmodified opinion on the financial statements.

Significance of the Results

The strong growth in revenue and profit indicates solid operational performance and market acceptance for Accretion Nutraveda's products. The board restructuring, with two new independent directors appointed, indicates a refreshed approach to governance and strategic oversight.

Company Overview

Accretion Nutraveda Ltd operates in the growing nutraceutical and health supplements market, focusing on natural and science-backed wellness solutions. The company has been on a growth trajectory, with its latest fiscal year performance highlighting its expanding market reach and product acceptance.

What changes now

• Shareholders can expect a continued focus on expanding the company's market share in the health and wellness segment.
• The addition of new independent directors may bring fresh perspectives to board discussions and strategic planning.
• Ongoing compliance and regulatory adherence will be maintained with the appointment of new auditors for the upcoming financial year.

Risks to watch

No specific risks were highlighted in the filing. However, as with any company undergoing board changes, smooth integration of new members and maintaining strong corporate governance are key.

Peer comparison

Accretion Nutraveda's latest performance shows significant growth compared to peers like VitaLife Sciences. While VitaLife Sciences reported revenue of approximately ₹65 crore in FY23, Accretion Nutraveda's FY26 revenue of ₹33.60 crore signifies a rapid ascent, particularly in its profit margins and growth rate.

Key Performance Metrics

• Revenue from operations grew by 110.3% from FY2025 (₹16.00 crore) to FY2026 (₹33.60 crore) on a standalone basis.
• Profit for the period increased by 102.6% from FY2025 (₹2.50 crore) to FY2026 (₹5.07 crore) on a standalone basis.

What to track next

• Shareholder voting and approval for the appointment of the new non-executive, independent directors.
• Management commentary on future growth strategies, product pipeline expansion, and market penetration.
• Quarterly financial results to monitor the sustainability of the current growth momentum.
• Any updates on the integration of new board members and their contributions to corporate governance.